Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E33.75 EPS (ttm)11.01 Insider Own1.20% Shs Outstand107.37M Perf Week0.89%
Market Cap39.89B Forward P/E21.45 EPS next Y17.32 Insider Trans-6.15% Shs Float79.06M Perf Month-3.09%
Income1.28B PEG1.93 EPS next Q4.50 Inst Own70.50% Short Float2.34% Perf Quarter-15.44%
Sales5.52B P/S7.23 EPS this Y39.50% Inst Trans-0.55% Short Ratio2.19 Perf Half Y-28.71%
Book/sh56.71 P/B6.55 EPS next Y10.63% ROA16.20% Target Price446.67 Perf Year2.23%
Cash/sh12.84 P/C28.93 EPS next 5Y17.44% ROE24.50% 52W Range340.09 - 543.55 Perf YTD-1.18%
Dividend- P/FCF49.70 EPS past 5Y38.80% ROI18.20% 52W High-31.65% Beta1.52
Dividend %- Quick Ratio3.30 Sales past 5Y61.30% Gross Margin93.40% 52W Low9.24% ATR8.20
Employees5400 Current Ratio3.60 Sales Q/Q23.00% Oper. Margin34.20% RSI (14)43.78 Volatility1.64% 2.24%
OptionableYes Debt/Eq0.12 EPS Q/Q45.90% Profit Margin23.20% Rel Volume0.78 Prev Close371.28
ShortableYes LT Debt/Eq0.12 EarningsFeb 08 BMO Payout0.00% Avg Volume844.10K Price371.53
Recom2.40 SMA20-1.80% SMA50-2.83% SMA200-14.77% Volume662,105 Change0.07%
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-17-18 09:03AM  Repatha Could Significantly Drive Amgens Revenue Growth in 2018 Market Realist
Jan-12-18 10:06AM  That Biotech M&A Wave? More like a Trickle Barrons.com
Jan-11-18 07:02PM  Cramer's lightning round: People might be bailing on Rege... CNBC Videos
06:51PM  Cramer's lightning round: People might be bailing on Regeneron, but it's a buy CNBC
10:19AM  Can Biotech Keep Last Year's Momentum Alive in 2018? Zacks
07:33AM  How Mylans Europe Segment Performed in 3Q17 Market Realist
Jan-10-18 05:20PM  How Did Bioverativ Perform in 3Q17? Market Realist
02:35PM  A Look at Ionis Pharmaceuticals January 2018 Valuation Market Realist
07:23AM  Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-09-18 05:47PM  Regeneron CEO talks drug pricing and tax reform CNBC Videos
05:00PM  3 Ways to trade biotech CNBC Videos
01:55PM  Finally, a Cure for Legalese The Wall Street Journal
10:23AM  Hows Incytes Valuation in January 2018? Market Realist
10:00AM  Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab Zacks
08:06AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
12:57AM  Rivals Help Fund Regenerons Gene-Sequencing Effort The Wall Street Journal
Jan-08-18 03:20PM  Regeneron forms consortium to accelerate gene sequencing project Reuters
09:05AM  Sanofi and Regeneron boost investment in cancer drug cemiplimab Reuters
08:12AM  What Are Analysts Saying About Regeneron Pharmaceuticals Incs (NASDAQ:REGN) Future? Simply Wall St.
07:04AM  Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs PR Newswire
07:02AM  Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs GlobeNewswire
07:00AM  Rivals Help Fund Regeneron's Gene-Sequencing Effort The Wall Street Journal
07:00AM  Regeneron forms consortium to accelerate gene sequencing project Reuters
07:00AM  Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank PR Newswire
Jan-04-18 08:35AM  Momenta & Mylan to Initiate Trial on Biosimilar of Eylea Zacks
Jan-03-18 05:40PM  Momenta, Mylan plan trial of biosimilar to Regeneron eye drug Reuters
Jan-02-18 04:08PM  Does Regeneron Pharma Have A Potential Blockbuster In 2018? Investor's Business Daily
09:20AM  Breakthrough drugs offer hope for the 360 million people with hearing loss CNBC
Dec-28-17 07:45PM  Is Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Expensive For A Reason? A Look At The Intrinsic Value Simply Wall St.
Dec-27-17 09:30AM  Regeneron Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-26-17 12:01PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-22-17 09:27AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017 Capital Cube
Dec-20-17 06:30AM  Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy Zacks
Dec-19-17 09:53AM  Regeneron in Strategic Immuno-Oncology Collaboration With ISA Zacks
07:28AM  The Zacks Analyst Blog Highlights: Disney, Kraft Heinz, Caterpillar, Humana and Regeneron Zacks
Dec-18-17 01:01AM  ISA Pharmaceuticals and Regeneron Announce Strategic Immuno-Oncology Collaboration GlobeNewswire
01:00AM  Regeneron and ISA Pharmaceuticals Announce Strategic Immuno-Oncology Collaboration PR Newswire
Dec-15-17 02:05PM  Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations Zacks
01:20PM  Beware: Price Wars For Big Pharma, Biotech Companies On Horizon Investor's Business Daily
11:15AM  Biotech Celgene May Rise 35% In 2018 Investopedia
Dec-14-17 07:11PM  Cramer's lightning round: Buy Regeneron, it's not getting... CNBC Videos
06:46PM  Cramer's lightning round: Buy Regeneron, it's not getting the credit it deserves CNBC
02:00PM  Sanofi Wants to Go It Alone -- Good Luck With That Bloomberg
12:38PM  Regenerons Kevzara Approved for Treatment of Rheumatoid Arthritis Market Realist
12:38PM  Regenerons Dupixent Approved for Atopic Dermatitis Market Realist
Dec-13-17 08:45PM  Will This Drug Kick-Start Regeneron Pharmaceuticals Shares? Motley Fool
05:45PM  Regeneron, Sanofi Report Positive Top Line Skin Cancer Data Zacks
11:25AM  Intercept: The Best of the Biotechs? Barrons.com
10:24AM  France's Sanofi pins hopes on new drugs after setbacks Reuters
06:24AM  Where Regeneron Pharmaceuticals Inc (undefined:REGN) Stands In Terms Of Earnings Growth Against Its Industry Simply Wall St.
04:42AM  France's Sanofi pins hopes on new drugs after setbacks Reuters
01:30AM  Regeneron Collaboration Programs Highlighted During Sanofi Analyst Day PR Newswire
01:02AM  Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma GlobeNewswire
01:01AM  Regeneron and Sanofi Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
Dec-12-17 05:49PM  Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set Zacks
Dec-11-17 07:54AM  Biopharma Schizophrenia: High Demand For Innovation Vs. Pleas For 'Me-Too' Drugs Forbes
07:00AM  Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD PR Newswire
03:22AM  Regeneron (REGN) Down 8.3% Since Earnings Report: Can It Rebound? Zacks
Dec-08-17 09:36AM  The Zacks Analyst Blog Highlights: Netflix, Stamps.com, Constellation Brands and Regeneron Pharmaceuticals Zacks
Dec-06-17 01:18PM  This Double Whammy Caused Regeneron Pharmaceuticals Inc. to Fall 10% in November Motley Fool
Dec-04-17 04:18PM  Amgen, Regeneron Prep For Battle In 2018 Over Cholesterol Drugs Investor's Business Daily
01:45PM  Analysts Recommendations for Regeneron Market Realist
12:15PM  How Regenerons Eylea and Praluent Performed in 3Q17 Market Realist
10:45AM  How Regeneron Pharmaceuticals Performed in 3Q17 Market Realist
Dec-01-17 09:57AM  Citi Downgrades Regeneron, Citing 'Underappreciated' Risk Benzinga
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Nov-30-17 06:28PM  Patent Move Was Nuts, Regeneron CEO Tells Allergan Chief Bloomberg
02:44PM  Regeneron CEO: Our genetics research is in the 'precompet... CNBC Videos
11:30AM  Here"s What"s Unusual About Regeneron Pharmaceuticals" Latest Deal GuruFocus.com
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
07:30AM  Tesla Is the Exception That Proves the Rule on Board Pay Bloomberg
Nov-29-17 08:08AM  Biotech Stock Roundup: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal Zacks
07:00AM  [$$] Decibel Therapeutics, Regeneron Strike Deal for Hearing Treatments The Wall Street Journal
07:00AM  Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus PR Newswire
Nov-28-17 01:30PM  What's Next For Regeneron After A Therapy Trial Failure? Benzinga
12:27PM  US and European Stocks in Green Tuesday GuruFocus.com
09:48AM  Regeneron Pharmaceuticals: Look but Don't Touch This Bruised Stock Just Yet TheStreet.com
09:42AM  Regeneron's Stock Falls as Mid-Stage Eye Disease Studies Fail Zacks
08:24AM  Regeneron Pharmaceuticals: Look but Don't Touch Just Yet TheStreet.com
Nov-27-17 04:24PM  Regeneron Dips To 7-Month Low After Drug Combo With Bayer Fails Investor's Business Daily
10:45AM  Regeneron's Eylea Protection Is Weakening Bloomberg
08:46AM  Regeneron stock declines 2% on abandoned eye disease therapy MarketWatch
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
07:20AM  Regeneron drops eye-drug combination as Novartis chases Eylea Reuters
02:00AM  Regeneron Provides Update on EYLEA® (aflibercept) Injection and Nesvacumab (Ang2 Antibody) Combination Program PR Newswire
Nov-24-17 08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Nov-20-17 08:08AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Nov-17-17 07:11PM  Cramers Exec Cut: The consumer trends business leaders h... CNBC Videos
Nov-15-17 09:30AM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
07:32AM  Inside Novartiss Ophthalmology Drugs Now Market Realist
06:37AM  Regeneron Pharmaceuticals: Cramer's Top Takeaways TheStreet.com
Nov-14-17 07:10PM  Regeneron CEO: Competitor Novartis is 'long on enthusiasm... CNBC Videos
07:10PM  Cramer Remix: My leftover question for GE is 'Did you mis... CNBC Videos
08:07AM  See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc. Markit
Nov-13-17 12:23PM  Poor earnings updates keep European shares at seven-week low Reuters
Nov-10-17 06:40PM  Edited Transcript of REGN earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
05:42PM  Novartis posts eye drug data amid play for Eylea's turf Reuters
Nov-09-17 10:53AM  When Will Biotech Bounce Back? Barrons.com
08:28AM  Biotech Stock Roundup: Regeneron Delivers Strong Q3 Results, Cellectis Clinical Hold Lifted Zacks
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreements with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor; and with Decibel Therapeutics, Inc. to discover and develop therapeutics for hearing loss and tinnitus. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; the U.S. Department of Health and Human Services to develop treatments combating infectious diseases; and ISA Pharmaceuticals. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fenimore Christopher R.VP ControllerJan 16Option Exercise21.251503,188150Jan 17 04:07 PM
SING GEORGE LDirectorJan 02Option Exercise23.8415,000357,600134,772Jan 03 04:13 PM
YANCOPOULOS GEORGEPresident & CSODec 13Option Exercise21.92195,4384,284,001786,786Dec 13 05:17 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise21.92250,0005,480,000407,409Dec 13 05:17 PM
VAGELOS P ROYChairman of the BoardDec 11Option Exercise21.92153,9693,375,000483,512Dec 13 04:53 PM
BROWN MICHAEL SDirectorOct 05Option Exercise177.821,500266,7301,500Oct 05 04:18 PM
BROWN MICHAEL SDirectorOct 05Sale475.001,500712,5000Oct 05 04:18 PM
BAKER CHARLES ADirectorSep 29Option Exercise18.612,00037,22011,000Oct 03 04:00 PM
BAKER CHARLES ADirectorSep 29Sale450.002,000900,0009,000Oct 03 04:00 PM
Landry Robert ESVP Finance & CFOSep 06Sale497.62474235,8737,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 05Sale501.0618994,7007,573Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOSep 01Option Exercise272.703,000818,10010,099Sep 06 05:06 PM
Landry Robert ESVP Finance & CFOAug 31Sale493.43427210,6937,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 30Option Exercise272.702,000545,4009,099Sep 01 04:04 PM
Landry Robert ESVP Finance & CFOAug 23Sale476.45468222,9817,099Aug 24 04:47 PM
Landry Robert ESVP Finance & CFOAug 22Option Exercise272.702,000545,4009,099Aug 24 04:47 PM
VAGELOS P ROYChairman of the BoardAug 22Sale477.6431,94415,257,816329,543Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 21Sale470.3224,26911,414,076361,487Aug 23 04:21 PM
VAGELOS P ROYChairman of the BoardAug 18Sale470.152,9001,363,435385,756Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 17Sale470.001,305613,350388,656Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Option Exercise21.92153,9693,375,000483,512Aug 18 05:00 PM
VAGELOS P ROYChairman of the BoardAug 16Sale470.1710,9865,165,288389,961Aug 18 05:00 PM
Terifay Robert JEVP CommercialAug 10Option Exercise52.031,92199,95025,214Aug 11 04:02 PM
Landry Robert ESVP Finance & CFOAug 08Sale472.19526248,3727,099Aug 09 04:03 PM
Landry Robert ESVP Finance & CFOAug 07Option Exercise272.702,000545,4009,099Aug 09 04:03 PM
STAHL NEILEVP Research and DevelopmentJun 22Sale532.558,3064,423,33223,950Jun 23 04:09 PM
Aberman Michael SSVP Strategy Investor RelationJun 22Sale532.422,2691,208,0614,693Jun 23 04:10 PM
Aberman Michael SSVP Strategy Investor RelationJun 21Option Exercise30.634,500137,8359,193Jun 23 04:10 PM
STAHL NEILEVP Research and DevelopmentJun 21Option Exercise30.6320,000612,60043,950Jun 23 04:09 PM
BROWN MICHAEL SDirectorJun 20Option Exercise177.823,000533,4603,000Jun 21 04:11 PM
GOLDSTEIN JOSEPH LDirectorJun 20Option Exercise273.671,000273,67014,000Jun 21 04:12 PM
GOLDSTEIN JOSEPH LDirectorJun 20Sale500.011,000500,01013,000Jun 21 04:12 PM
BROWN MICHAEL SDirectorJun 20Sale500.003,0001,500,0000Jun 21 04:11 PM
Terifay Robert JEVP CommercialJun 16Sale468.1921,1479,900,81423,293Jun 19 04:44 PM
Terifay Robert JEVP CommercialJun 15Option Exercise52.0348,7502,536,46372,043Jun 19 04:44 PM
STAHL NEILEVP Research and DevelopmentJun 15Sale468.458,5674,013,17723,950Jun 16 04:36 PM
STAHL NEILEVP Research and DevelopmentJun 14Option Exercise21.2520,295431,26944,245Jun 16 04:36 PM
BROWN MICHAEL SDirectorJun 12Option Exercise177.822,000355,6402,000Jun 14 04:36 PM
BROWN MICHAEL SDirectorJun 12Sale474.452,000948,8900Jun 14 04:36 PM
GOLDSTEIN JOSEPH LDirectorJun 09Option Exercise273.671,000273,67014,000Jun 13 05:06 PM
GOLDSTEIN JOSEPH LDirectorJun 09Sale482.551,000482,55013,000Jun 13 05:06 PM
STAHL NEILEVP Research and DevelopmentJun 02Sale479.492,8121,348,31423,950Jun 05 04:52 PM
STAHL NEILEVP Research and DevelopmentJun 01Option Exercise198.3810,5442,091,72430,814Jun 05 04:52 PM
VAGELOS P ROYChairman of the BoardMay 25Sale458.149,2954,258,37383,652May 26 04:04 PM
BROWN MICHAEL SDirectorMay 12Option Exercise177.823,000533,4603,000May 15 04:07 PM
BROWN MICHAEL SDirectorMay 12Sale450.003,0001,350,0000May 15 04:07 PM
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM